ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Conditions.
On March12, 2018, we issued a press released titled “Zosano Pharma Reports Fourth Quarter and Fiscal 2017 Financial Results and Operational Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.
The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 2.02 Financial Statements and Exhibits.
Zosano Pharma Corp ExhibitEX-99.1 2 d463579dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update First patient enrolled in long term safety study in November 2017 Pivotal efficacy data for M207 published in October 2017 Allowed patent application to be issued in March 2018 extends proprietary position for M207 to 2037 FREMONT,…To view the full exhibit click
About ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN)
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.